(3)干安能(Epivir)拉米夫定片(贺普丁)=Lamivudine
(4)干適能(Adefovir=Hepsera)阿德福韦酯片=Adefovir Dipivoxil.
(5)貝樂克(Baraclude) 恩替卡韦片(博路定)=Entecavir.
(6)Tyzeka 替比夫定片(素比伏)=Telbivudine
approved by FDA in 2006 by China in 2006。
(7)Clevudine(L-FMAU)克拉夫定Levovir (Oked  by S. Korea in 2006). 
***Based on Korean clinical trial, Clevudine is ,amoung 7 medicine's
best as far as the side effects and efficacies is concerned.*** Details please
refer the test reports included in this article. Regretably to say, American FDA is sill under clinical trial phase 3 not yet approved and marketed in U.S. 

台灣有300萬B型肝炎帶原大軍，平均每八個人就有一人;中國有13,000萬,平均每10個人就有一人B肝是造成肝硬化、肝癌的主因，抑制病毒不斷複製的「肝淨」工程，是減少肝臟受損的重要關鍵，新一代口服抗病毒藥物清肝效果佳且較無抗藥性，但是健保不給付，治療四年恐要48萬元;中國no data。  ＠ http://udn.com  

成功大學醫學院內科教授張定宗指出，B肝治療的目標是消除或永久抑制B肝病毒。目前B肝病患有選擇7種，藥物包括打針的長、短效干擾素(1+2)，口服抗病毒藥物則包括(3)(干安能(Epivir)、(4)干適能(Adefovir=Hepsera)、(5)貝樂克(Baraclude) (6)Tyzeka approved by FDA in 2006 by China in 2006。(7)Clevudine(L-FMAU)Levovir (Approved by S. Korea in 2006).  干安能,(mikkyhan has used for 9 years and so far so good.)、干適能每天一顆，藥費分別為110元、240元，在健保尚不給付的年代，救肝一年要價四萬(Epivir) {Mikkyhan's suggested dosage cost 救肝一年要價2萬}到八萬元，而病患通常需要吃到四年。新藥預估一年要12萬元，如連吃4年就要48萬元,(Entecavir) 預估一年要33萬元如連吃4年就要133萬元. How many patient can afford it?。Another 3 new drugs under clinic trial in phase III. There are (FTC) (Ldt) &(L-FMU). The future for HBV
treatment looks bright! 

由於治療期間很長，病患就出現了抗藥性問題，使用最廣的干安能第一年就有二成出現抗藥，第四年七成出現抗藥性(It does not mean that you can not continue taking Epivir.)。干適能第一年沒有抗藥性**wrong information from this news report. 1st year Hepsera has 43% resistance**，第四年約有一成八出現抗藥性。

最近藥廠又推出救肝新藥貝樂克(Entecavir)=Baraclude，臨床研究發現，八成病患使用之後，病毒量低到檢測不到 Reference blog http://city.udn.com/v1/blog/article/article.jsp?uid=
mikkyhan&f_ART_ID=426851。
Muir Lodge for Sale 3M
http://www.yosemitemuirlodge.com/4sale.htm
Owner retire 27 room+43 acres
140 HWY creek frontage

【2006/08/31 聯合晚報】
Met Dr.Ambreen Khurshid, M.D. of Gastroenterology on 9/7/06. I asked what her opinion about those liver HBV druges. I told my search on google that among those 3 namely
干安能(Epivir)干適能(Adefovir=Hepsera)、and 貝樂克(Baraclude), Hepsera has 43%
有抗藥性 and 貝樂克(Baraclude) though sounds better (remains to be testimonial proven)
price 8 times higher, Epivir is still favorable to the HBV patients and doctors. In America,
medicine is not covered by medicare and insurance. You have to pay from your pocket.
Dr. Kurshid agreed.
Congratulation to HBV patients in China! 素比伏(Sebivo) is prices cheaper than Epivir.
由於慢性B肝患者需要長期追蹤治療，時間可能長達數年，他建議，B型肝炎帶原者每3~6個月須做一次肝功能和α蛋白檢查，半年做一次腹部超音波，並定期追蹤體內病毒量，以了解是否有抗藥性的情形；當肝功能數值正常，血中e抗原轉陰性或消失，繼續追蹤3﹣6月，即表示肝炎獲控制，原則上毋需再服藥。UDN 6/8/2007 

[转帖]国外5种正在临床研究的乙肝新药